Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Pirtobrutinib

Review the clinical trials studying pirtobrutinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Status: Active
Location: 14 locations
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Status: Active
Location: 9 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
Glofitamab and Obinutuzumab with or without Polatuzumab Vedotin, Pirtobrutinib or Atezolizumab for the Treatment Richter's Transformation
Status: Active
Location: 4 locations
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: 4 locations
Venetoclax and Pirtobrutinib for the Treatment of Previously Treated Waldenstrom Macroglobulinemia
Status: Active
Location: 3 locations
Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for the Treatment of Previously Untreated Mantle Cell Lymphoma
Status: Active
Location: 2 locations
Pirtobrutinib and Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: 2 locations
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Pirtobrutinib in Combination with Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Combination of Pirtobrutinib and Venetoclax for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Pirtobrutinib, Venetoclax, and Obinutuzumab for the Treatment of Untreated Chronic Lymphocytic Leukemia or Untreated, Recurrent, or Refractory Richter Transformation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pirtobrutinib in Combination with Rituximab for Controlling Disease in Patients with Newly Diagnosed Low or Intermediate Risk Mantle Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Glofitamab with Pirtobrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania